Drug interactions
Tisagenlecleucel + Ustekinumab
Severity: Major
Tisagenlecleucel and Ustekinumab: major interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Tisagenlecleucel is a CAR-T cell therapy given after lymphodepletion, and immunosuppressants such as ustekinumab may blunt CAR-T expansion and efficacy. They may also add to the infection risk in an already immunocompromised patient.
What this interaction means in plain words
Tisagenlecleucel and Ustekinumab can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Tisagenlecleucel belongs to Oncology; Ustekinumab belongs to Gastrointestinal Tract.
Why it happens
Immunosuppression may impair CAR-T cell expansion and persistence and adds to infection risk.
What to do
Avoid ustekinumab in the period around leukapheresis and CAR-T infusion where possible. Monitor for infection and treatment response if it cannot be avoided.
What to ask your pharmacist
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Tisagenlecleucel and Ustekinumab, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Ustekinumab
- Bcg vaccine live + Ustekinumab Contraindicated
- Typhoid vaccine live + Ustekinumab Contraindicated
- Adalimumab + Ustekinumab Major
- Adenovirus types 4 and 7 live + Ustekinumab Major
- Alefacept + Ustekinumab Major
- Anakinra + Ustekinumab Major
Other interactions of Tisagenlecleucel
Frequently asked questions
Can I take Tisagenlecleucel with Ustekinumab?
MediHelp rates the interaction as major. Tisagenlecleucel and Ustekinumab can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Tisagenlecleucel is a CAR-T cell therapy given after lymphodepletion, and immunosuppressants such as ustekinumab may blunt CAR-T expansion and efficacy. They may also add to the infection risk in an already immunocompromised patient.
How serious is the interaction between Tisagenlecleucel and Ustekinumab?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid ustekinumab in the period around leukapheresis and CAR-T infusion where possible. Monitor for infection and treatment response if it cannot be avoided.
What other medicines interact with Ustekinumab?
MediHelp also lists interactions of Ustekinumab with, for example, Bcg vaccine live, Typhoid vaccine live, Adalimumab. The full list is on the Ustekinumab page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
